心肌病基因变异与多基因风险评分在房颤中的研究:支持心房优先表型
在UKB和AoU两个队列共655,796人中,致病性心肌病基因变异与房颤风险升高相关(HR 1.73),调整突发心室心肌病或临床心衰后仍显著(HR 1.55)。提示这些基因对房颤风险的影响常等同或超过对心肌病的影响。
要点
- 心肌病致病基因变异携带者房颤风险显著增加,独立于心室心肌病和心衰。
- 联合房颤PRS可区分携带者更易发生心房还是心室表型。
- 这些基因虽为心肌病病因,但对房颤风险影响常等同或更大。
核心结论
- 致病性心肌病基因变异增加房颤风险,即使无心力衰竭或明显心室疾病。
- 结合疾病特异性PRS有助于识别携带者更可能发生心房或心室疾病。
- 这些基因对房颤风险的影响常等同或大于对心肌病的影响。
研究设计与样本
- 研究纳入UKB和AoU两个队列共655,796人,采用Cox回归评估致病性变异与房颤关联。
- 对房颤、DCM和HCM的PRS按五分位分层,并用DerSimonian-Laird法进行HR随机效应荟萃分析。
- 采用Kaplan-Meier法计算从出生至75岁的累积发病率。
主要发现
- 携带致病性变异与房颤风险升高相关(HR 1.73;95%CI 1.59-1.89;P<0.001)。
- 调整突发心室心肌病或临床心衰后,HR为1.55(95%CI 1.46-1.64;P<0.001)。
- 携带变异且房颤PRS最高五分位者累积房颤风险为32.5%(UKB)和32.4%(AoU)。
- 无变异且房颤PRS最低五分位者累积房颤风险为9.8%(UKB)和11.0%(AoU)。
- 携带变异且疾病特异性PRS最高五分位者累积心肌病风险:DCM为5.9%(UKB)至15.2%(AoU),HCM为11.7%(UKB)至19.1%(AoU)。
临床怎么用
- 对心肌病致病基因变异携带者应评估房颤风险,即使无心室疾病或心衰。
- 可结合房颤PRS和疾病特异性PRS判断携带者更易发生房颤还是心肌病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atrial fibrillation (AF) is heritable and its complex underlying genetic substrate is gradually being unraveled. OBJECTIVES: We sought to explore the impact of disease-causing cardiomyopathy variants on the risk of AF after adjustment for incident ventricular cardiomyopathy and clinical heart failure in 2 cohort studies (UK Biobank [UKB] and All of Us [AoU]) and evaluate the utility of polygenic risk scores (PRS) to further discern the risk of atrial and ventricular phenotypes in carriers. METHODS: Cox regression was used to evaluate for associations between disease-causing variants within genes for 3 cardiomyopathies (dilated cardiomyopathy [DCM], hypertrophic cardiomyopathy [HCM], and arrhythmogenic right ventricular cardiomyopathy) and AF. Disease-specific PRSs for AF, DCM, and HCM stratified study participants into quintiles. A HR random-effects meta-analysis was performed using the DerSimonian-Laird method. The Kaplan-Meier method was used to ascertain cumulative incidence from birth to 75 years of age. RESULTS: Among 655,796 individuals from UKB and AoU, presence of a disease-causing variant was associated with an increased AF hazard (HR: 1.73; 95% CI: 1.59-1.89; P < 0.001), including after adjustment for incident ventricular cardiomyopathy or clinical heart failure (adjusted to HR: 1.55; 95% CI: 1.46-1.64, P < 0.001). The cumulative AF risk for study participants with a putative disease-causing rare variant and a PRSAF within the top-risk quintile ranged from 32.5% (UKB) to 32.4% (AoU) relative to 9.8% (UKB) and 11.0% (AoU) for individuals without a putative disease-causing variant and a PRSAF within the lowest-risk quintile. The absolute cumulative cardiomyopathy risk among study participants with both a putative disease-causing variant and a disease-specific PRS within the top-risk quintile ranged from 5.9% (UKB) to 15.2% (AoU) for DCM and from 11.7% (UKB) to 19.1% (AoU) for HCM. CONCLUSIONS: Genetic variants that cause cardiomyopathy also increase the risk of AF, even in individuals without heart failure or overt ventricular disease. Combining disease-specific PRSs with these variants helps identify whether a person is more likely to develop atrial or ventricular disease. Although discovered as causes of cardiomyopathy, these genes often have an equal or greater impact on the risk of AF.
引用
- da Rocha GL, Feiner J, Lazarte J, et al. Cardiomyopathy Gene Variants and Polygenic Risk Scores in Atrial Fibrillation: Evidence for an Atrial-First Phenotype. J Am Coll Cardiol. 2026. PMID: 41706057. doi:10.1016/j.jacc.2025.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。